METOX

Product Overview

METOX is a South Korean botulinum toxin type A product marketed by Maypharm Co., Ltd. Available in METOX 100 Units and METOX 200 Units, the product contains Clostridium botulinum toxin type A formulated with human serum albumin and sodium chloride. Both strengths are supplied as dried powder in transparent, single-dose glass vials and require refrigerated storage at 2–8°C.

METOX belongs to the category of botulinum toxin type A neuromodulators used in professional medical aesthetics. Its active ingredient temporarily inhibits acetylcholine release at peripheral cholinergic nerve terminals, reducing neuromuscular signaling and the contraction of affected skeletal muscles.

The METOX product range includes two labeled potency presentations: 100U and 200U. Both contain the same type of active neurotoxin, while the total biological potency and certain excipient quantities differ between the formulations.

Maypharm markets METOX for aesthetic applications involving facial expression lines, including glabellar lines and lateral canthal lines. These applications are described in the company's commercial product documentation; their regulatory authorization must be verified separately for each destination country.

This TEOSQUARE product page covers METOX 100U and METOX 200U, providing professional buyers with information about product composition, formulation characteristics, vial strengths, packaging, storage requirements, and regulatory considerations.

Key Features

• Botulinum Toxin Type A: Contains Clostridium botulinum toxin type A, a neurotoxic protein that temporarily inhibits acetylcholine release at susceptible peripheral nerve terminals.
• 100U and 200U Strengths: Available in two commercial presentations containing 100 or 200 units of labeled biological potency per vial.
• Albumin-Containing Formulation: Includes human serum albumin and sodium chloride as pharmaceutical excipients.
• Dried Powder Presentation: Supplied as a dried botulinum toxin preparation in a transparent glass vial. Commercial documents describe vacuum-drying technology, while the 200U brochure also uses freeze-dried terminology.
• Single-Vial Packaging: Commonly supplied in individual manufacturer-style packages containing one vial of the selected potency.
• Refrigerated Storage: Published METOX product documentation specifies storage at 2°C to 8°C for unopened vials.
• Maypharm Product Portfolio: METOX is marketed by Maypharm Co., Ltd., a South Korean medical aesthetics company offering botulinum toxin and dermal filler products.

Composition & Specifications

METOX contains Clostridium botulinum toxin type A as its active ingredient. Human serum albumin and sodium chloride are identified as excipients in published METOX product specifications.

The active ingredient is expressed in biological potency units rather than milligrams. A labeled unit represents product-specific biological activity and must not automatically be considered equivalent to a unit of another botulinum toxin preparation.

Clostridium Botulinum Toxin Type A

Botulinum toxin type A is a neurotoxic protein produced by Clostridium botulinum. Pharmaceutical preparations containing this substance are used to temporarily inhibit neurotransmitter release at susceptible peripheral nerve terminals.

METOX is described in Maypharm's commercial documentation as a purified botulinum neurotoxin complex. The company markets the product in two strengths containing 100 or 200 units of botulinum toxin type A per vial.

The pharmacological action of botulinum toxin type A involves interference with proteins responsible for the release of acetylcholine. This reduces neuromuscular transmission and produces temporary relaxation of affected skeletal muscles.

METOX potency units are product-specific. They should not be directly converted into equivalent quantities of BOTOX, Dysport, Xeomin, MEDITOXIN, or other botulinum toxin products.

Human Serum Albumin

Human serum albumin is a protein commonly used as a stabilizing excipient in certain biological pharmaceutical formulations.

Albumin-containing formulations may use the protein to support the stability of biologically active ingredients during manufacturing, storage, and handling.

Published METOX specifications identify 0.5 mg of human serum albumin in the 100U formulation and 1.0 mg in the 200U formulation.

These quantities should be confirmed against the original product labeling and manufacturer-issued documentation for the supplied batch.

Sodium Chloride

Sodium chloride is included as a formulation excipient. It contributes to the physicochemical characteristics of the dried pharmaceutical preparation.

Commercial product documentation identifies sodium chloride in both METOX strengths. However, published quantities are not entirely consistent across suppliers.

One professional distributor identifies 0.8 mg for METOX 100U and 1.8 mg for METOX 200U, while another commercial specification reports 0.9 mg for the 100U formulation.

Exact excipient quantities should be verified using the original manufacturer-issued specifications. Distributor-reported ingredient amounts should not replace the approved formulation documentation applicable to the supplied product.

Dried Powder Formulation

METOX is supplied as a dried pharmaceutical preparation rather than a ready-to-use liquid solution.

Several commercial descriptions identify vacuum-drying technology as a characteristic of the METOX formulation. Maypharm's published 200U brochure also describes the product as a freeze-dried white powder.

These descriptions are not fully consistent in their terminology. A definitive distinction between vacuum-drying and freeze-drying for each commercial presentation requires confirmation from the manufacturer.

The appearance of a dried botulinum toxin preparation, including the amount of visible residue in the vial, does not independently establish protein purity, potency, stability, or clinical effectiveness.

METOX 100U and 200U should be identified by their original product labels and potency declarations. The drying method and formulation specifications should be confirmed from manufacturer-controlled technical documentation.

How METOX Botulinum Toxin Type A Works

METOX contains botulinum toxin type A, which temporarily reduces neuromuscular transmission by inhibiting acetylcholine release at susceptible peripheral nerve terminals.

This pharmacological mechanism is characteristic of botulinum toxin type A preparations and provides the scientific basis for their use in selected aesthetic and therapeutic applications.

Neuromuscular Signal Transmission

Under normal physiological conditions, motor neurons transmit signals to skeletal muscles through the release of acetylcholine at the neuromuscular junction.

Acetylcholine binds to receptors on muscle cells and initiates the electrical processes responsible for muscle contraction.

Botulinum toxin type A interferes with this signaling process by acting within susceptible nerve terminals.

SNAP-25 and Neurotransmitter Release

Botulinum toxin type A contains an enzymatically active light chain that cleaves SNAP-25, a protein involved in the SNARE complex responsible for neurotransmitter vesicle fusion.

Disruption of SNAP-25 function reduces the release of acetylcholine into the neuromuscular junction.

The reduction in acetylcholine release temporarily decreases neuromuscular signaling and the contraction of affected skeletal muscles.

Temporary Muscle Relaxation

Reduced neuromuscular signaling produces temporary muscle relaxation or weakness.

In appropriately authorized aesthetic applications, this mechanism can reduce the appearance of dynamic wrinkles associated with repeated facial muscle contraction.

Dynamic wrinkles differ from static wrinkles because their appearance is directly influenced by muscle movement.

Recovery of Neuromuscular Function

The effects of botulinum toxin type A are temporary. Neuromuscular function may gradually recover through biological processes involving nerve-terminal recovery and restoration of neurotransmission.

The onset, magnitude, and duration of an individual product's clinical effects depend on its formulation, permitted indication, administration conditions, and patient-specific factors.

A specific duration of action should not be assigned to METOX solely on the basis of studies involving other botulinum toxin products.

The mechanism described above is established for botulinum toxin type A as a pharmacological class. It does not demonstrate identical efficacy, duration, or potency equivalence between METOX and other commercial botulinum toxin preparations.

Available METOX Variants

The METOX product family includes two commercially documented strengths: METOX 100 Units and METOX 200 Units.

Both contain Clostridium botulinum toxin type A and are supplied as dried powder in single-dose glass vials. Their primary difference is the total labeled biological potency per vial.

METOX 100 Units

METOX 100U contains 100 units of Clostridium botulinum toxin type A per vial.

The formulation is supplied as dried powder in a transparent glass vial. Commercial product specifications describe a white to pale-yellow preparation.

Published composition information identifies human serum albumin and sodium chloride as excipients, with human serum albumin commonly listed at 0.5 mg per vial.

METOX 100U is commercially positioned for professional aesthetic applications involving dynamic facial wrinkles.

Its exact authorized indications, regulatory status, and product-specific prescribing requirements must be verified for the destination country.

METOX 200 Units

METOX 200U contains 200 units of Clostridium botulinum toxin type A per vial.

Maypharm's published METOX 200U brochure describes the product as a dried white powder containing botulinum toxin type A.

Professional distribution specifications identify 1.0 mg human serum albumin and 1.8 mg sodium chloride as excipients in the 200U formulation.

The 200U presentation provides twice the total labeled biological potency of the 100U vial.

This difference does not mean that each individual unit is more potent, produces a stronger clinical effect, or has a longer duration of action.

The 200U formulation is commercially positioned for professional medical aesthetic applications. Its approved indications and clinical use restrictions must be confirmed through the applicable official product documentation.

METOX 100U and 200U are separate potency presentations. A higher total unit count does not establish greater potency per unit or justify direct conversion between METOX and other botulinum toxin products.

METOX Product Identification

METOX is part of Maypharm's botulinum toxin portfolio, which also includes the separately marketed KAMOMIS brand.

METOX and MEDITOXIN are different commercial product families. METOX is associated with Maypharm, while MEDITOXIN is a separate botulinum toxin brand developed by Medytox.

Similarities in product names, active ingredient categories, or labeled units do not establish identical manufacturing processes, formulations, regulatory authorizations, or clinical performance.

Professional buyers should identify METOX using the original product name, labeled potency, manufacturer or marketing company details, batch information, and market-specific documentation.

Maypharm identifies METOX as part of its commercial portfolio. The precise legal manufacturing facility and current regulatory authorizations should be established using the original manufacturer documentation and relevant national registration records.

Packaging & Product Presentation

METOX 100U and 200U are commonly supplied as individual dried-powder formulations in transparent glass vials.

Maypharm-associated commercial documentation and product packaging identify single-vial presentations for both strengths.

Certain distributors offer different commercial quantities, including multi-vial purchasing options. These should not automatically be interpreted as official manufacturer box configurations.

The unit designation on the vial represents biological potency rather than a liquid volume or recommended administration quantity.

Original manufacturer labeling should be used to verify the product name, potency, lot number, expiration date, company information, and applicable regulatory documentation.

The documented standard presentation is one vial per box. Exact packaging contents and market-specific configurations should be confirmed against the supplied product.

Storage & Handling

Published METOX product documentation specifies refrigerated storage between 2°C and 8°C for unopened vials.

Maypharm's METOX 200U brochure identifies a shelf life of up to 24 months under the specified refrigerated storage conditions.

The applicable shelf life and storage instructions for each supplied product should be confirmed using its original manufacturer labeling.

• Refrigerated Storage: Store unopened METOX vials at 2°C to 8°C according to published product specifications.
• Temperature-Controlled Distribution: Maintain appropriate temperature conditions throughout storage and transportation.
• Original Packaging: Keep the product in its original manufacturer packaging until required for authorized professional use.
• Container Integrity: Inspect the original vial and packaging for damage, leakage, or other indications of compromised integrity.
• Product Traceability: Verify the labeled potency, batch number, expiration date, manufacturer information, and relevant regulatory documentation.
• Professional Handling: Follow the product-specific official instructions for preparation, administration, and disposal.

Requirements for a prepared solution differ from those for an unopened dried-powder vial. Preparation and handling after preparation must comply with the applicable product-specific instructions.

The 24-month shelf life is documented in Maypharm's METOX 200U commercial brochure. Do not assume the same expiration period applies to every product presentation without checking its original label.

Safety & Regulatory Considerations

METOX contains botulinum toxin type A, a potent biological substance that affects neuromuscular transmission. Professional use requires appropriate medical expertise and compliance with the applicable pharmaceutical regulations.

Potential Adverse Reactions

Adverse reactions associated with botulinum toxin type A products may include injection-site discomfort, swelling, bruising, headache, and unintended weakness of nearby muscles.

Other complications may include eyelid drooping, facial asymmetry, and functional changes resulting from unintended effects on surrounding muscles.

The incidence and severity of adverse events depend on the particular product, clinical indication, administration conditions, and patient-related factors.

Potential Spread of Toxin Effects

Botulinum toxin products can cause serious adverse reactions if their biological effects extend beyond the intended treatment area.

Potential complications associated with this drug class include generalized muscle weakness, difficulty swallowing, speech disturbances, and breathing difficulties.

These reactions may require urgent medical assessment.

Contraindications and Precautions

Patients with known hypersensitivity to botulinum toxin type A or formulation components, or an active infection at the intended administration site, may have contraindications to treatment.

Certain neuromuscular disorders and medications affecting neuromuscular transmission may require additional precautions.

METOX contains human serum albumin, and applicable safety considerations relating to human-derived biological excipients should be reviewed.

Non-Interchangeable Potency Units

Biological potency units for botulinum toxin preparations are established using product-specific testing methods.

METOX 100U and 200U should not be directly converted into equivalent quantities of BOTOX, Dysport, Xeomin, MEDITOXIN, or other botulinum toxin products.

Similar labeled unit counts do not establish identical biological activity, clinical response, duration of effect, or safety profiles across different brands.

Regulatory Authorization

METOX is commercially marketed by Maypharm for professional medical aesthetic applications.

However, the current product-specific regulatory authorization status and approved prescribing information for every destination market have not been independently established.

Published commercial descriptions of glabellar-line or lateral-canthal-line applications should not be interpreted as confirmation of an approved indication without the corresponding national regulatory authorization.

US FDA approval for METOX has not been established. Authorization of other botulinum toxin type A products does not extend automatically to METOX.

Professional buyers should verify the product's legal classification, registration status, manufacturer documentation, import eligibility, distribution restrictions, and permitted indications before procurement.

This information is intended for professional product identification and commercial evaluation. It does not provide administration instructions, replace official prescribing information, establish patient suitability, or authorize unapproved clinical applications.

Frequently Asked Questions